The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Mechanisms Of Gastroesophageal Reflux In Obstructive Sleep Apnoea
Funder
National Health and Medical Research Council
Funding Amount
$462,214.00
Summary
The symptoms of gastroesophageal reflux (heartburn and acid burning) are extremely common in individuals with obstructive sleep apnoea (OSA), especially during sleep (nocturnal reflux). The reasons for this are unclear. This research project will investigate the reasons for this increased occurrence of reflux in OSA.
Efficacy Of Ablative Therapies For Barrett's Oesophagus
Funder
National Health and Medical Research Council
Funding Amount
$570,148.00
Summary
Some people with severe reflux develop Barrett's oesophagus, which puts them at high risk of developing cancer. Patients with Barrett's can be treated with various endoscopic ablation techniques, but it is not yet know if these treatments prevent the development of cancer. The aims of this work are to use molecular methods to ascertain whether the tissue that regenerates after ablation is normal, and to compare different ablation techniques.
Long Term Follow-up Of Randomised Controlled Trials For Laparoscopic Antireflux Surgery
Funder
National Health and Medical Research Council
Funding Amount
$712,100.00
Summary
17% of Australians use medication for gastro-oesophageal reflux, with many requiring tablets life long. In >15% this is not adequate. The alternative is surgery which is the only curative treatment for reflux and hiatus hernia. It achieves a good outcome in 90%, although some develop further reflux or side effects. To reduce problems procedures have been modified. In a series of trials we are evaluating long term outcomes for modifications, to determine the best surgical treatment for reflux.
Regulated Intracellular Trafficking Of A Potassium Channel In Gastric Acid-secreting Cells
Funder
National Health and Medical Research Council
Funding Amount
$609,511.00
Summary
The cells of our bodies possess proteins that transport salts and other chemicals. These transport proteins must be correctly positioned in cells, a process that is poorly understood. If transport proteins are not positioned properly then diseases such as heart attack or diabetes may occur. Influencing the position of transport proteins may also be used to treat disease. This work investigates how a transport protein that shuttles potassium is correctly positioned in cells of the stomach.
Improving Oesophageal Adenocarcinoma Outcomes Through Understanding Genomics And Treatment Toxicity.
Funder
National Health and Medical Research Council
Funding Amount
$1,013,282.00
Summary
Oesophageal adenocarcinoma is an aggressive cancer, as most patients will not survive for more than 5 years. Therefore we need to find better ways to treat patients. In this study we will identify the DNA mutations in oesophageal cancers that were part of clinical trial. The data allow us to determine why some tumours responded well to therapy, and why some patients had serious side effects to the treatment. The results will help inform on selection of therapy for future patients.
Blood Serum MicroRNA Biomarkers For Oesophageal Cancer
Funder
National Health and Medical Research Council
Funding Amount
$495,433.00
Summary
Oesophageal adenocarcinoma (OAC) is the 6th commonest cause of cancer deaths in the Western World, and is increasing in incidence. In Australia most patients present late and require risky treatments with a low cure rate. There is a big difference in survival between individuals presenting early vs. late. Better methods to detect cancer early or detect pre-cancer will improve outcomes. Our research will develop a blood test for identifying individuals with early OAC to allow earlier treatment.
Over half of all cancers contain mutations in a gene called TP53, also known as the “guardian of the genome”. Mutation of TP53 provides tumour cells with a growth advantage, and leads to resistance to chemotherapy and poor outcomes for patients. We have identified a potential “Achilles heel” in cancers with TP53 mutations. In this project we will establish a new paradigm for treating tumours with TP53 mutations that will be applicable to a large number of patients across all types of cancer.
DOCetaxel With Or Without Radiation Therapy For Resectable Oesophageal Adenocarcinoma Based On Early PET Response To Induction Chemotherapy (DOCTOR).
Funder
National Health and Medical Research Council
Funding Amount
$1,024,738.00
Summary
Oesophageal cancer continues to have poor survival despite surgery. Patients responding to pre-operative chemotherapy have better survival than those who do not. This study proposes using early FDG-PET scan to identify patients not responding to standard chemotherapy. This will permit the timely change of therapy to alternative regimens with a newer agent with or without radiotherapy, aiming to improve outcomes. This represents a paradigm shift in the management of oesophageal cancer.
Which Modifiable Risk Factors Actually Cause Cancer?
Funder
National Health and Medical Research Council
Funding Amount
$384,076.00
Summary
Observational studies suggest that modifiable risk factors such as low vitamin D levels, coffee consumption, alcohol consumption and obesity may be important in cancer risk. However, observational studies can only demonstrate association between a risk factor and cancer, and association does not equal causation. We present an alternative approach to help determine which risk factors actually cause cancer.
Identification Of Biomarkers Of Response And Toxicity To Chemoradiotherapy For Oesophageal Tumours
Funder
National Health and Medical Research Council
Funding Amount
$496,935.00
Summary
Chemoradiotherapy for oesophageal tumours has high interpatient variability in response and toxicity to treatment. Predictive biomarkers of response and toxicity would help select patients who would benefit most from this treatment modality. The proposed project will determine blood-derived microRNA and mRNA profiles that identify patients according to risk of unfavourable treatment outcomes, enabling clinicians to offer personalised alternative treatment strategies for those patients.